Editas Medicine Remains on Track

Editas Medicine (NASDAQ: EDIT) announced second-quarter 2019 results on Tuesday after the market closed, once again confirming its on track to move forward with a historic dose-escalation trial for its primary drug candidate, EDIT-101, while advancing its agenda for future experimental medicines. The genome-editing specialist also named a permanent CEO to stand at the helm following the surprise departure of its last chief executive earlier this year.

Let's slice deeper, then, to better understand how EDITAS ended the first half, as well as its plans for coming quarters.

IMAGE SOURCE: GETTY IMAGES.

Continue reading

Quelle Fool.com